Bile duct cancer is known to contain numerous fibroblasts, and reported to Multivariate analyses also demonstrated that the stromal matriptase expression level was an independent influential factor in RFS (P ¼ 0.0050) and OS (P ¼ 0.0093). Our findings suggest that the high stromal matriptase expression was strongly associated with tumor progression, recurrence and poor outcomes in patients with extrahepatic bile duct cancer.
D and matriptase were evaluated immunohistochemically. Staining intensities and distribution were scored, and finally classified into low and high expression groups in cancer cells and stroma respectively. High expression of matriptase in the cancer stroma was detected in 91 tumors (40%). The high stromal matriptase expression was significantly associated with shorter recurrence-free survival (RFS) and overall survival (OS) (P ¼ 0.0027 and 0.0023, respectively).
Multivariate analyses also demonstrated that the stromal matriptase expression level was an independent influential factor in RFS (P ¼ 0.0050) and OS (P ¼ 0.0093). Our findings suggest that the high stromal matriptase expression was strongly associated with tumor progression, recurrence and poor outcomes in patients with extrahepatic bile duct cancer.
K E Y W O R D S
cancer stroma, extrahepatic bile duct cancer, matriptase, platelet-derived growth factor-D, survival analysis Extrahepatic bile duct cancer is a devastating disease with a very poor prognosis. 1, 2 There is higher incidence in Asian countries including Japan. 2 The desmoplastic reaction is one of the features of bile duct cancer, and the lesion often contains a large number of fibroblasts. 1 The tumor associated stroma composed of fibroblasts, capillaries and immune cells is the site of complex functional interactions between cancer cells and the host microenvironment, and it plays a pivotal role in tumor growth and invasion. 3 Cancer-associated 
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antiapoptotic signals that ultimately promote cancer growth. 3, 4 On the other hand, cancer cells produce a range of signals able to instruct the stromal microenvironment to become permissive and supportive for tumor progression. 4 In bile duct cancer, overexpression of proinflammatory cytokines in the tumor stroma is associated with a more malignant tumor phenotype. 5 Moreover, paracrine signals from CAFs protect bile duct cancer cells from proapoptotic stimuli. 6 Members of the platelet-derived growth factor (PDGF) family are of particular interest to the interactions between cancer cells and their surrounding stroma, because of their ability to promote fibroblast migration and proliferation. 7 There are four PDGF ligands (PDGF-A, ÀB, ÀC, and ÀD) that exert their biological functions through binding to their cognate receptors, PDGFRa and PDGFRb. PDGF-A and ÀB undergo intracellular proteolytic processing by furin before they are secreted as readily active growth factor dimers. 8 In contrast, PDGF-C and PDGF-D are secreted as latent growth factor dimers with an N-terminal CUB domain, a C-terminal growth factor domain, and the hinge region in between. 9,10 Proteolytic removal of the CUB domain is required for the growth factor domain of the PDGF-C and ÀD to activate the PDGFRa and PDGFRb, respectively.
9,10
Serine proteases, such as urokinase plasminogen activator (uPA) and matriptase, can remove the CUB domain in a stepwise manner. 11 Especially, matriptase was reported to act as a regulator of PDGF-D in prostate cancer.
12
Matriptase is an epithelial-specific type II transmembrane serine protease shown to be upregulated in many cancers. 13 Matriptase's repertoire of substrates includes the pro-forms of hepatocyte growth factor (HGF), PDGF-C and ÀD, uPA, and extracellular matrix (ECM) components such as collagen type IV. [12] [13] [14] Consequently, matriptase regulates proteolytic signaling networks as well as ECM remodeling, and thus it is being considered as a classic promoter of invasive growth of tumors. 15 Bile duct cancer cells were reported to recruit CAFs by secreting PDGF-D. 16, 17 Therefore, matriptase, PDGF-D activated by matriptase, and CAFs recruited by PDGF-D are assumed to influence the prognosis of the patients with extrahepatic bile duct cancer. However, it is unclear how much impact these factors have on clinical outcomes. In this present study, we investigated the relationship between immunohistochemical expression patterns of matriptase and PDGF-D and prognosis in patients with extrahepatic bile duct cancer. were not assessed in this study. Alternatively, we divided patients into two groups according to the depth of tumor: those with carcinoma in situ or the tumor suspected slight invasion but its extension was up to the muscle layer or fibrous tissue (microinvasion), and those with the obviously invasive tumor. They included some patients who received Macroscopic residual tumor 22 (9) No data 9 (3)
MATERIALS AND METHODS

Patients recruitment
Other therapy, n (%) 
Tissue microarray (TMA) construction
All cases were available for formalin-fixed, paraffin-embedded tissue blocks that contained cancer, and hematoxylin and eosin (HE) stained slides of the specimens were reviewed by board-certified anatomic pathologists to ascertain the diagnostic accuracy. From each case, one to two tissue blocks including main tumor tissue were selected. Two tissue core samples of 3 mm in diameter per tumor were obtained from these blocks. Each core was chosen as much as possible to reflect on their heterogeneity of tumor differentiation. Four tumor samples, in which TMA samples could not be obtained for technical problems, were prepared as conventional whole tissue sections from formalin-fixed, paraffin-embedded tissue blocks as substitutes.
Immunohistochemistry
Immunohistochemical staining was conducted using the "Labelled polymer method" with EnVisionþ Dual Link System-HRP (Dako, Agilent Pathology Solutions, Santa Clara, CA, USA). The rabbit polyclonal IgG antibody against human PDGF-D (catalog#: 40-2100) was purchased from Invitrogen (Thermo Fisher Scientific, Waltham, MA, USA), and the rabbit polyclonal IgG antibody ST14/matriptase (catalog#: LS-B904) was purchased from LSBio (LifeSpan BioSciences, Seattle, WA, USA). The 4 mm-thick sections were cut from paraffin-embedded tissue blocks. Following deparaffinization and rehydration in graded concentraions of ethanol, antigen retrieval treatment was performed at 95°C (microwave) for 10 min in a pH 6.0 citrate buffer solution proior to treatment with 0.3% hydrogen peroxide methanol for 30 min to quench endogenous peroxidase activity. The slides were incubated with primary antibodies against PDGF-D (dilution, 1:50) or matriptase (dilution, 1:200) overnight at 4°C. Sections were incubated with horseradish peroxidase (HRP) labelled polymer which is conjugated with secondary antibodies (EnVisionþ Dual Link System-HRP) for 2 h at room temperature. Peroxidase activity was detected with diaminobenzene solution. The slides were counterstained with 1% Mayer's hematoxylin. Immunohistochemical expression levels of the PDGF-D and matriptase were evaluated in both cancer cells and their surrounding stroma. All slides were examined and scored independently by two pathologists (TK and NF), who were blind to the clinical information of the study participants. In a few cases where evaluation differed, agreement was reached by consensus using a two-headed microscope.
Staining intensities and proportions of positive areas were evaluated in both membrane and cytoplasm of cancer cells. Staining intensity was scored on a 4-point scale: 0 (none), 1 (weakly positive), 2 (moderately positive) or 3 (strongly positive). Proportion of positive areas (areas of positive cancer cells or stroma/areas of total cancer cells or stroma) was scored on a 4-point scale: 0, <25%; 1, 25% to <50%; 2, 50% to <75%; 3, !75%. Composite scores were derived by adding the intensity score to the proportion score. Tumor stromal expression was also evaluated in the same way. This evaluation excluded the cases with "carcinoma in situ or microinvasion", since we could not define where the cancer stroma was in these tumor. If the tumor showed discrepant intensities and/or proportion of positive areas in two core samples, we adopted higher score in both analyses, cancer cells and cancer stroma.
Statistical analysis
All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics. 19 Fisher's exact test was used to test possible associations between the expression of PDGF-D or matriptase, in the cancer cells or stroma, and clinicopathological factors (age, gender, main location, depth of invasion, lymph node metastasis, venous invasion, lymphatic invasion and perineural invasion). Kaplan-Meier curves were plotted to assess the association between expression of PDGF-D or matriptase, in the cancer cells or stroma and recurrencefree survival (RFS) or overall survival (OS). Survival curves were compared using log-rank test. In these analyses, the patients who categorized into "Residual tumor (macroscopic or microscopic)" group were excluded, since these patients showed significantly shorter RFS and OS than the other groups in univariate and multivariate analyses. were set at "0 month". A value of P < 0.05 was considered statistically significant.
RESULTS
Immunohistochemistry for PDGF-D and matriptase in cancer cells
Most cancer cells were moderately to strongly stained with PDGF-D and matriptase immunohistochemically. Expressions were predominantly located in cytoplasm, with some in the nucleus or membrane of the cancer cells (Fig. 1) . Adjacent non-malignant epithelial cells exhibited weak or no staining of PDGF-D. However, there were non-malignant epithelial cells stained with matriptase in some tumors (Fig. S1 ). Since all cancer cells were generally stained with PDGF-D and matriptase, the composite scores tended to be high. We set the cut-off point at 5 to divide the cases into two groups, high and low expression, for statistical analyses. The composite scores of !5 were defined as high expression, and scores of <5 were defined as low expression. There was a reason that other cut-off points extremely biased the groups toward one side. High expression of cytoplasmic PDGF-D and matriptase was detected in 83 (32%) and 126 (48%) tumors, and low expression of these was detected in 173 (67%) and 130 (51%) tumors, respectively. High expression of PDGF-D and matriptase in the cancer cells was observed more often in invasive cancers than carcinoma in situ or microinvasive cancers (P ¼ 0.049, 0.014, respectively), and they had significant correlation with venous invasion (P ¼ 0.038, 0.00094, respectively). High expression of matriptase in the cancer cells was significantly correlated with perineural invasion (P ¼ 0.044) ( Table 2) . Regarding survival analyses, high expression of matriptase in cancer cells was associated with shorter OS (P ¼ 0.048), but not RFS (P ¼ 0.087). High expression of PDGF-D in cancer cells was not associated with neither OS nor RFS (P ¼ 0.12, 0.092, respectively). 
Immunohistochemistry for PDGF-D and matriptase in cancer stroma
In some tumors the cancer stroma highly expressed PDGF-D or matriptase immunohistochemically (Fig. 1) . Expression of PDGF-D was localized almost in fibroblast.
However, that of matriptase was detected not only fibroblasts, but also inflammatory cells, endothelial cells and matrix of the stroma. In contrast to the staining in the cancer cells, stromal expressions showed various levels, and then it was easier to classify into high or low expression group. We set the cut-off point at 4 to divide the cases into two groups, high and low expression, for statistical analyses. The composite scores of !4 were defined as high expression, and scores of <4 were defined as low expression. This cutoff point was not biased and appropriate to conduct statistical analyses. High expression of PDGF-D and matiptase in the cancer stroma was detected in 60 (26%) and 91 (40%) tumors, respectively. High expression of PDGF-D in the cancer stroma had significant correlation only with lymphatic invasion (P ¼ 0.0034). Meanwhile, high expression of matriptase in the cancer stroma was significantly correlated with lymph node metastasis, venous invasion and lymphatic invasion (P ¼ 0.028, 0.032 and 0.00039, respectively) ( Table 2 ). Survival analyses indicated that high expression of PDGF-D in cancer stroma was associated with shorter OS (P ¼ 0.027), but not RFS (P ¼ 0.11), while high expression of matriptase in cancer stroma was significantly associated with shorter OS and RFS (P ¼ 0.0023, 0.0027, respectively). Association between PDGF-D and matriptase expression in cancer cells and stroma was showed in Table 3 . PDGF-D and matriptase were associated each other, then the tumor, which expressed PDGF-D, tended to express matriptase in both cancer cells and stroma.
Prognostic significance of matriptase expression in cancer stroma
As mentioned above, matriptase expression in the cancer stroma was associated with significantly shorter RFS and OS time relative to the negative group (RFS; n, 53 vs. 81 months; 5-year RFS rate, 31.4 vs. 53.6 %; 95% confidence interval (CI), 18.5-45.2 vs. 41.1-64.6%; P ¼ 0.0027, OS; n, 49 vs. 77 months; 5-year OS rate 34.8 vs. 59.1%; 95% CI, 20.8-49.2 vs. 45.9-70.0%; P ¼ 0.0023) (Fig. 2) . The prognostic relevance of matriptase expression in the cancer stroma was assessed using a multivariate proportional hazards regression model. Matriptase expression in the cancer stroma was determined to be an independent prognostic factor (RFS; hazard ratio (HR), 1.7; 95%CI, 1.2-2.4; P ¼ 0.0050, OS; HR, 1.7; 95%CI, 1.2-2.5; P ¼ 0.0093). Residual tumor was also correlated with RFS and OS independently (RFS; HR, 2.6; 95%CI, 1.9-3.5; P < 0.0001, OS; HR, 2.3; 95%CI, 1.7-3.2; P < 0.0001) ( Table 4) .
DISCUSSION
In this study, we confirmed extrahepatic bile duct cancer cells commonly expressed PDGF-D and matriptase as previously reported in other cancers. 13, 20 In addition, the tumor stromal higher matriptase expression was significantly associated with shorter RFS and OS time comparing to the lower expression group. Furthermore, multivariate analyses indicated that tumor stromal matriptase expression was an independent prognostic factor. Matriptase have been focused on its potential roles in carcinogenesis, and many studies demonstrated that matriptase is upregulated in various types of cancers using various methods, including real-time PCR, Western blotting and immunohistochemistry. [21] [22] [23] [24] [25] [26] [27] [28] In common with other cancers previously reported, our data showed that extrahepatic bile duct cancer cells expressed PDGF-D and matriptase generally. However, we could not demonstrate the significant relationship between those expression levels and OS or RFS (except for high expression of matriptase in the cancer cells and shorter OS). These results may be led by the difficulty of differentiating tumors, because most cancer cells were moderately to strongly stained with PDGF-D and matriptase immunohistochemically.
As far as we searched in the English literature, no studies have focused on expression levels of PDGF-D and matriptase in cancer stroma. In our study, however, stromal expression levels of PDGF-D and matriptase were various in extrahepatic bile duct cancer, and the higher stromal matriptase expression group showed significantly shorter RFS and OS time comparing to the lower expression group. Activated matriptase is rapidly inhibited by hepatocyte growth factor activator inhibitor-1 (HAI-1), then the matriptase-HAI-1 complex is shed from the plasma membrane. 29 This may be the reason why the matrix was stained with matiptase immunohistochemically. Matriptase does not only trigger specific responses, including cell proliferation, migration, inflammatory cytokine production, inflammatory cell recruitment, hyperplasia, and fibrosis, 30 but also regulates the activities of PDGF-D by its dynamic proteolytic processing. 12 We showed extrahepatic bile duct cancer cells commonly expressed PDGF-D similar to other cancers. In the tumor with stromal expression of matriptase, CAFs, which constitute the cancer stroma, can use PDGF-D as a ligand and recruit more CAFs. Then, recruited CAFs may cause poor prognosis in patients with extrahepatic bile duct cancer. It was probable that PDGF-D and matriptase were closely related each other. Multivariate analyses indicated that only residual tumor and stromal matriptase expression was correlated with RFS and OS independently. Although lymph node metastasis was not determined to be correlated only with RFS, lymphatic invasion had correlation with OS. It is a wellknown fact that lymph node metastasis and residual tumor were reported as a prognostic factor in the previous studies, 31, 32 while stromal matriptase expression was newly detected in our present study. Consequently, the stromal matriptase expression is likely to reflect malignant potential, however the mechanism of this stromal expression has been unknown and must be clarified. Although fibroblasts in the cancer stroma seemed to be stained with matriptase, other components were also stained with matriptase. We could not understand what significance there was. Additionally, even if the fibroblasts expressed matriptase, it is unclear whether the fibroblasts use PDGF-D as a ligand actually. Thus, further studies elucidating the mechanism of stromal matriptase expression are warranted.
In conclusion, it is the first report that higher stromal expression of matriptase was significantly associated with poorer prognosis of patients with extrahepatic bile duct cancer. Stromal matriptase may be involved in progression of extrahepatic bile duct cancer.
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